AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

14,302.00p
   
  • Change Today:
    472.00p
  • 52 Week High: 15,252.00
  • 52 Week Low: 9,667.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.97m
  • Volume: 2,660,473
  • Market Cap: £221,819m
  • RiskGrade: 123
  • Beta: 0.00

Latest ShareCast News

AstraZeneca's COPD candidate succeeds in twin Phase III studies

By Iain Gilbert

Date: Friday 27 Mar 2026

(Sharecast News) - Drugmaker AstraZeneca said on Friday that its monoclonal antibody tozorakimab had met the primary endpoint in both of its Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 14,302.00p
Change Today 472.00p
% Change 3.41 %
52 Week High 15,252.00
52 Week Low 9,667.00
Volume 2,660,473
Shares Issued 1,550.97m
Market Cap £221,819m
Beta 0.00
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average
90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average
Price Trend
9.16% above the market average9.16% above the market average9.16% above the market average9.16% above the market average9.16% above the market average
45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average
Income
68.72% below the market average68.72% below the market average68.72% below the market average68.72% below the market average68.72% below the market average
Sector averageSector averageSector averageSector averageSector average
Growth
87.64% above the market average87.64% above the market average87.64% above the market average87.64% above the market average87.64% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 13
Neutral 3
Sell 0
Strong Sell 1
Total 27
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 19-Feb-26 07-Aug-25
Paid 23-Mar-26 08-Sep-25
Amount 217.00¢ 103.00¢

Trades for 27-Mar-2026

Time Volume / Share Price
15:46 0 @ 14,332.00p
15:46 0 @ 14,332.00p
15:46 0 @ 14,332.00p
15:32 1 @ 14,332.00p
15:19 0 @ 14,310.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page